Status:
TERMINATED
Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Aventis Pharmaceuticals
Conditions:
HIV Infections
Eligibility:
FEMALE
21-50 years
Phase:
PHASE1
Brief Summary
It is probable that a mucosal approach is necessary for a prophylactic HIV vaccine protecting against sexually transmitted infection. Mucosal immune responses have been almost non-existent in trials o...
Detailed Description
It's probable that a mucosal approach is necessary for prophylactic HIV vaccine protecting against sexually transmitted infection. Although mucosal immune responses have been almost non-existent in tr...
Eligibility Criteria
Inclusion
- Women chosen in a uniform selection process specifically designed by the ANRS (French National Agency for Research on AIDS and Viral Hepatitis)
- For women of child-bearing age : use of effective contraception
- Normal clinical status
- Ability to accept collection of secretion fluids;
- Ability to sign informed consent
Exclusion
- Pregnancy
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
April 1 2005
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00122564
Start Date
June 1 2003
End Date
April 1 2005
Last Update
November 11 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Tenon
Paris, France, 75012